Wen Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wen Zheng has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Shaoping Nie
Capital Medical University
7 shared publications - Xiao Wang
Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
6 shared publications Hui Ai
Beijing Anzhen Hospital, Capital Medical University
4 shared publicationsBin Que
Center for Coronary Artery Disease, Division of Cardiology, Beijing Anzhen Hospital Capital Medical University Beijing China
3 shared publicationsQian Guo
Center for Coronary Artery Disease, Division of Cardiology Beijing Anzhen Hospital, Capital Medical University Beijing China
3 shared publicationsWei Gong
Center for Coronary Artery Disease, Division of Cardiology Beijing Anzhen Hospital, Capital Medical University Beijing China
3 shared publications
Latest Publications
- Open Access
- 28 July 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (7) , 33439
Association of Obstructive Sleep Apnea With Cardiovascular Events in Acute Coronary Syndrome Patients With or Without Excessive Daytime Sleepiness: A Prospective Cohort Study
Background: Excessive daytime sleepiness (EDS) is a commonly observed symptom in people with obstructive sleep apnea (OSA). However, the impact of EDS on the outcome of patients with acute coronary syndrome (ACS) and OSA is not known. Therefore, this study aimed to investigate the association between OSA and cardiovascular events in ACS patients with or without EDS. Methods: This cohort study prospectively enrolled eligible ACS patients who underwent cardiorespiratory polygraphy during hospitalization between June 2015 and January 2020. We defined OSA as an apnea–hypopnea index (AHI) ≥15 events per h. EDS was described as having an Epworth Sleepiness Scale score ≥10. Major adverse cerebrovascular and cardiovascular events (MACCEs) were the primary outcome and included cardiovascular death, stroke, myocardial infarction, ischemia-driven revascularization, or hospitalization for heart failure or unstable angina. Results: The final study cohort comprised 1154 participants, of whom 398 (34.5%) had EDS, and 607 (52.6%) had OSA. During the median follow-up period of 2.9 years (interquartile range 1.5, 3.6), OSA was associated with a significantly increased risk of MACCEs in patients without EDS (adjusted hazard ratio (HR) = 1.42, 95% CI: 1.01–2.02, p = 0.046), but not in patients with EDS (adjusted hazard ratio HR = 1.05, 95% CI: 0.67–1.66, p = 0.84). Conclusions: OSA was associated with an elevated risk of MACCEs In ACS patients without EDS but not those with EDS. Therefore, screening for OSA should be performed in ACS patients without EDS, and future trials should prioritize such high-risk patients. Clinical Trial Registration: NCT03362385, https://clinicaltrials.gov/study/NCT03362385.
- 28 July 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (7) , 33439
Open AccessAssociation of Obstructive Sleep Apnea With Cardiovascular Events in Acute Coronary Syndrome Patients With or Without Excessive Daytime Sleepiness: A Prospective Cohort Study
Background: Excessive daytime sleepiness (EDS) is a commonly observed symptom in people with obstructive sleep apnea (OSA). However, the impact of EDS on the outcome of patients with acute coronary syndrome (ACS) and OSA is not known. Therefore, this study aimed to investigate the association between OSA and cardiovascular events in ACS patients with or without EDS. Methods: This cohort study prospectively enrolled eligible ACS patients who underwent cardiorespiratory polygraphy during hospitalization between June 2015 and January 2020. We defined OSA as an apnea–hypopnea index (AHI) ≥15 events per h. EDS was described as having an Epworth Sleepiness Scale score ≥10. Major adverse cerebrovascular and cardiovascular events (MACCEs) were the primary outcome and included cardiovascular death, stroke, myocardial infarction, ischemia-driven revascularization, or hospitalization for heart failure or unstable angina. Results: The final study cohort comprised 1154 participants, of whom 398 (34.5%) had EDS, and 607 (52.6%) had OSA. During the median follow-up period of 2.9 years (interquartile range 1.5, 3.6), OSA was associated with a significantly increased risk of MACCEs in patients without EDS (adjusted hazard ratio (HR) = 1.42, 95% CI: 1.01–2.02, p = 0.046), but not in patients with EDS (adjusted hazard ratio HR = 1.05, 95% CI: 0.67–1.66, p = 0.84). Conclusions: OSA was associated with an elevated risk of MACCEs In ACS patients without EDS but not those with EDS. Therefore, screening for OSA should be performed in ACS patients without EDS, and future trials should prioritize such high-risk patients. Clinical Trial Registration: NCT03362385, https://clinicaltrials.gov/study/NCT03362385.
- Open Access
Association between Charlson Comorbidity Index and in-hospital outcomes among aortic stenosis patients undergoing aortic valve replacement: an observational study at the National Clinical Research Center for Cardiovascular Diseases
Objectives This study aimed to evaluate the impact of the Charlson Comorbidity Index (CCI) on in-hospital outcomes in patients with aortic stenosis (AS) undergoing aortic valve replacement (AVR) and to compare the efficacy of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with different comorbidity burdens. Setting The National Clinical Research Center for Cardiovascular Diseases. Participants A retrospective analysis was conducted on 3380 AS patients who underwent AVR in Beijing Anzhen Hospital from January 2015 to October 2021. Interventions Patients were stratified into low (0–1) and high (≥2) CCI groups. Primary and secondary outcome measures The primary outcome was Valve Academic Research Consortium-2 (VARC-2) composite early safety endpoints. Results Patients with high CCI scores exhibited significantly higher rates of VARC-2 composite adverse outcomes compared with those with low scores (50.3% vs 44.2%, p=0.001). After adjusting for confounding factors, high CCI scores were independently associated with the VARC-2 composite adverse outcomes (OR=1.36, 95% CI 1.17 to 1.58, pConclusions CCI is a significant predictor of in-hospital composite adverse events in AS patients undergoing AVR. TAVR may be preferred over SAVR for patients aged ≥65 years, irrespective of comorbidity burden, to minimise composite events risk. These findings underscore the importance of considering comorbidity burden in treatment decision-making for AS patients. Trial registration number NCT05797402.
Open AccessAssociation between Charlson Comorbidity Index and in-hospital outcomes among aortic stenosis patients undergoing aortic valve replacement: an observational study at the National Clinical Research Center for Cardiovascular Diseases
Objectives This study aimed to evaluate the impact of the Charlson Comorbidity Index (CCI) on in-hospital outcomes in patients with aortic stenosis (AS) undergoing aortic valve replacement (AVR) and to compare the efficacy of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with different comorbidity burdens. Setting The National Clinical Research Center for Cardiovascular Diseases. Participants A retrospective analysis was conducted on 3380 AS patients who underwent AVR in Beijing Anzhen Hospital from January 2015 to October 2021. Interventions Patients were stratified into low (0–1) and high (≥2) CCI groups. Primary and secondary outcome measures The primary outcome was Valve Academic Research Consortium-2 (VARC-2) composite early safety endpoints. Results Patients with high CCI scores exhibited significantly higher rates of VARC-2 composite adverse outcomes compared with those with low scores (50.3% vs 44.2%, p=0.001). After adjusting for confounding factors, high CCI scores were independently associated with the VARC-2 composite adverse outcomes (OR=1.36, 95% CI 1.17 to 1.58, pConclusions CCI is a significant predictor of in-hospital composite adverse events in AS patients undergoing AVR. TAVR may be preferred over SAVR for patients aged ≥65 years, irrespective of comorbidity burden, to minimise composite events risk. These findings underscore the importance of considering comorbidity burden in treatment decision-making for AS patients. Trial registration number NCT05797402.
- Open Access
- 17 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (6) , e036719
Effect of Intensive Blood Pressure Control and Comorbidity Status on the Prognosis of Patients With Hypertension: Insights From SPRINT
Background: Hypertension is common and leads to negative outcomes. Intensive blood pressure (BP) lowering can reduce cardiovascular events and all‐cause mortality, but its benefits for patients with hypertension with multiple comorbidities are uncertain. This study aimed to explore how comorbidities affect the clinical outcomes of intensive BP lowering in participants from the SPRINT (Systolic Blood Pressure Intervention Trial). Methods: We analyzed data from the SPRINT data set and calculated each patient's comorbidity score using the Charlson Comorbidity Index (CCI). The primary end point was major adverse cardiovascular and cerebrovascular events, including cardiovascular death, heart failure, myocardial infarction, acute coronary syndrome not leading to myocardial infarction, and stroke. Secondary end points included each component of the primary end point and all‐cause death. Results: We categorized 9361 patients into 3 groups based on CCI scores: 0, 1 to 2, and ≥3. Patients with higher CCI scores had more cardiovascular and cerebrovascular comorbidities. Intensive BP treatment significantly lowered the risk of major adverse cardiovascular and cerebrovascular events in patients with CCI scores of 0 (7.1% versus 10.9%; adjusted hazard ratio [HR], 0.634 [95% CI, 0.474–0.848]; P =0.002) and 1 to 2 (12. 8% versus 17.2%; adjusted HR, 0.729 [95% CI, 0.588–0.905]; P =0.004), but not in those with CCI ≥3 (23.3% versus 23.5%; adjusted HR, 0.907 [95% CI, 0.683–1.206]; P =0.502). It also reduced the risk of cardiovascular mortality across all CCI groups. Subgroup analyses revealed that intensive BP lowering was beneficial for major adverse cardiovascular and cerebrovascular events in most demographic and clinical subgroups with mild or moderate comorbidities. However, in the severe comorbidity subgroup, its benefits were limited to patients with atrial fibrillation. Certain medications, such as nonselective β‐blockers and diuretics, were associated with higher major adverse cardiovascular and cerebrovascular event risk in patients with mild comorbidities, whereas others showed varying effects based on comorbidity severity. Conclusions: Intensive BP control decreased cardiovascular events and mortality in patients with mild or moderate comorbidity burden, particularly in those with mild comorbidities. This emphasizes the importance of optimizing BP management even in patients with hypertension without extensive comorbid conditions, as their risk may be underestimated. Registration: URL: clinicaltrials.gov ; Unique Identifier: NCT01206062.
- 17 March 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (6) , e036719
Open AccessEffect of Intensive Blood Pressure Control and Comorbidity Status on the Prognosis of Patients With Hypertension: Insights From SPRINT
Background: Hypertension is common and leads to negative outcomes. Intensive blood pressure (BP) lowering can reduce cardiovascular events and all‐cause mortality, but its benefits for patients with hypertension with multiple comorbidities are uncertain. This study aimed to explore how comorbidities affect the clinical outcomes of intensive BP lowering in participants from the SPRINT (Systolic Blood Pressure Intervention Trial). Methods: We analyzed data from the SPRINT data set and calculated each patient's comorbidity score using the Charlson Comorbidity Index (CCI). The primary end point was major adverse cardiovascular and cerebrovascular events, including cardiovascular death, heart failure, myocardial infarction, acute coronary syndrome not leading to myocardial infarction, and stroke. Secondary end points included each component of the primary end point and all‐cause death. Results: We categorized 9361 patients into 3 groups based on CCI scores: 0, 1 to 2, and ≥3. Patients with higher CCI scores had more cardiovascular and cerebrovascular comorbidities. Intensive BP treatment significantly lowered the risk of major adverse cardiovascular and cerebrovascular events in patients with CCI scores of 0 (7.1% versus 10.9%; adjusted hazard ratio [HR], 0.634 [95% CI, 0.474–0.848]; P =0.002) and 1 to 2 (12. 8% versus 17.2%; adjusted HR, 0.729 [95% CI, 0.588–0.905]; P =0.004), but not in those with CCI ≥3 (23.3% versus 23.5%; adjusted HR, 0.907 [95% CI, 0.683–1.206]; P =0.502). It also reduced the risk of cardiovascular mortality across all CCI groups. Subgroup analyses revealed that intensive BP lowering was beneficial for major adverse cardiovascular and cerebrovascular events in most demographic and clinical subgroups with mild or moderate comorbidities. However, in the severe comorbidity subgroup, its benefits were limited to patients with atrial fibrillation. Certain medications, such as nonselective β‐blockers and diuretics, were associated with higher major adverse cardiovascular and cerebrovascular event risk in patients with mild comorbidities, whereas others showed varying effects based on comorbidity severity. Conclusions: Intensive BP control decreased cardiovascular events and mortality in patients with mild or moderate comorbidity burden, particularly in those with mild comorbidities. This emphasizes the importance of optimizing BP management even in patients with hypertension without extensive comorbid conditions, as their risk may be underestimated. Registration: URL: clinicaltrials.gov ; Unique Identifier: NCT01206062.
- Open Access
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e036729
Association of Obstructive Sleep Apnea and Nocturnal Hypoxemia With the Circadian Rhythm of Myocardial Infarction
Background: The circadian rhythm of myocardial infarction (MI) in patients with obstructive sleep apnea (OSA) remains disputable and no studies have directly evaluated the relationship between nocturnal hypoxemia and the circadian rhythm of MI. The aim of the current study was to evaluate the association of OSA and nocturnal hypoxemia with MI onset during the night. Methods: Patients with MI in the OSA‐acute coronary syndrome (ACS) project (NCT03362385) were recruited. The time of MI onset was identified by patient's report of the chest pain that prompted hospital admission. All patients underwent an overnight sleep study using a type III portable sleep monitoring device after clinical stabilization during hospitalization. The difference in circadian variation of MI onset was evaluated between patients with moderate/severe OSA and non/mild OSA and those with or without nocturnal hypoxemia. Nocturnal hypoxemia was evaluated using 3 variables, including oxygen desaturation index, minimum oxygen saturation, and total sleep time with saturation P =0.008). Only in patients with both moderate/severe OSA and nocturnal hypoxemia, including oxygen desaturation index ≥15, minimum oxygen saturation ≤86%, and total sleep time with saturation P =0.01) and nocturnal hypoxemia (oxygen desaturation index ≥15 model, adjusted odds ratio 1.80, [95% CI, 1.21–2.66]; minimum oxygen saturation ≤86% model, adjusted odds ratio 1.70 [95% CI, 1.16–2.47]; P =0.006; total sleep time with saturation P =0.03) significantly predicted MI occurrence from midnight to 6:00 am . Conclusions: A peak of incident MI onset between midnight to 5:59 am was observed in patients with moderate/severe OSA, especially in those presenting with nocturnal hypoxemia.
- 4 February 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (3) , e036729
Open AccessAssociation of Obstructive Sleep Apnea and Nocturnal Hypoxemia With the Circadian Rhythm of Myocardial Infarction
Background: The circadian rhythm of myocardial infarction (MI) in patients with obstructive sleep apnea (OSA) remains disputable and no studies have directly evaluated the relationship between nocturnal hypoxemia and the circadian rhythm of MI. The aim of the current study was to evaluate the association of OSA and nocturnal hypoxemia with MI onset during the night. Methods: Patients with MI in the OSA‐acute coronary syndrome (ACS) project (NCT03362385) were recruited. The time of MI onset was identified by patient's report of the chest pain that prompted hospital admission. All patients underwent an overnight sleep study using a type III portable sleep monitoring device after clinical stabilization during hospitalization. The difference in circadian variation of MI onset was evaluated between patients with moderate/severe OSA and non/mild OSA and those with or without nocturnal hypoxemia. Nocturnal hypoxemia was evaluated using 3 variables, including oxygen desaturation index, minimum oxygen saturation, and total sleep time with saturation P =0.008). Only in patients with both moderate/severe OSA and nocturnal hypoxemia, including oxygen desaturation index ≥15, minimum oxygen saturation ≤86%, and total sleep time with saturation P =0.01) and nocturnal hypoxemia (oxygen desaturation index ≥15 model, adjusted odds ratio 1.80, [95% CI, 1.21–2.66]; minimum oxygen saturation ≤86% model, adjusted odds ratio 1.70 [95% CI, 1.16–2.47]; P =0.006; total sleep time with saturation P =0.03) significantly predicted MI occurrence from midnight to 6:00 am . Conclusions: A peak of incident MI onset between midnight to 5:59 am was observed in patients with moderate/severe OSA, especially in those presenting with nocturnal hypoxemia.
- 12 December 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Medical Imaging
- Vol. 44 (3) , 1541-1555
Slice2Mesh: 3D Surface Reconstruction From Sparse Slices of Images for the Left Ventricle
Cine MRI is a widely used technique to evaluate left ventricular function and motion, as it captures temporal information. However, due to the limited spatial resolution, cine MRI only provides a few sparse scans at regular positions and orientations, which poses challenges for reconstructing dense 3D cardiac structures, which is essential for better understanding the cardiac structure and motion in a dynamic 3D manner. In this study, we propose a novel learning-based 3D cardiac surface reconstruction method, Slice2Mesh, which directly predicts accurate and high-fidelity 3D meshes from sparse slices of cine MRI images under partial supervision of sparse contour points. Slice2Mesh leverages a 2D UNet to extract image features and a graph convolutional network to predict deformations from an initial template to various 3D surfaces, which enables it to produce topology-consistent meshes that can better characterize and analyze cardiac movement. We also introduce As Rigid As Possible energy in the deformation loss to preserve the intrinsic structure of the predefined template and produce realistic left ventricular shapes. We evaluated our method on 150 clinical test samples and achieved an average chamfer distance of 3.621 mm, outperforming traditional methods by approximately 2.5 mm. We also applied our method to produce 4D surface meshes from cine MRI sequences and utilized a simple SVM model on these 4D heart meshes to identify subjects with myocardial infarction, and achieved a classification sensitivity of 91.8% on 99 test subjects, including 49 abnormal patients, which implies great potential of our method for clinical use.
- 12 December 2024
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Medical Imaging
- Vol. 44 (3) , 1541-1555
Slice2Mesh: 3D Surface Reconstruction From Sparse Slices of Images for the Left Ventricle
Cine MRI is a widely used technique to evaluate left ventricular function and motion, as it captures temporal information. However, due to the limited spatial resolution, cine MRI only provides a few sparse scans at regular positions and orientations, which poses challenges for reconstructing dense 3D cardiac structures, which is essential for better understanding the cardiac structure and motion in a dynamic 3D manner. In this study, we propose a novel learning-based 3D cardiac surface reconstruction method, Slice2Mesh, which directly predicts accurate and high-fidelity 3D meshes from sparse slices of cine MRI images under partial supervision of sparse contour points. Slice2Mesh leverages a 2D UNet to extract image features and a graph convolutional network to predict deformations from an initial template to various 3D surfaces, which enables it to produce topology-consistent meshes that can better characterize and analyze cardiac movement. We also introduce As Rigid As Possible energy in the deformation loss to preserve the intrinsic structure of the predefined template and produce realistic left ventricular shapes. We evaluated our method on 150 clinical test samples and achieved an average chamfer distance of 3.621 mm, outperforming traditional methods by approximately 2.5 mm. We also applied our method to produce 4D surface meshes from cine MRI sequences and utilized a simple SVM model on these 4D heart meshes to identify subjects with myocardial infarction, and achieved a classification sensitivity of 91.8% on 99 test subjects, including 49 abnormal patients, which implies great potential of our method for clinical use.
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (19) , e029252
In‐Hospital Mortality and Treatment in Patients With Acute Coronary Syndrome With and Without Standard Modifiable Cardiovascular Risk Factors: Findings From the CCC‐ACS Project
Background: Patients with acute coronary syndrome without standard modifiable cardiovascular risk factors (SMuRFs; hypertension, smoking, dyslipidemia, diabetes) have not been well studied, with little known about their characteristics, quality of care, or outcomes. We sought to systematically analyze patients with ACS without SMuRFs, especially to evaluate the effectiveness of guideline‐directed medical therapy for these patients. Methods and Results: In the CCC‐ACS (Improving Care for Cardiovascular Disease in China‐Acute Coronary Syndrome) project (2014–2019), we examined the presence and absence of SMuRFs and features among 89 462 patients with initial acute coronary syndrome. The main outcome was in‐hospital all‐cause mortality. Among eligible patients, 11.0% had none of the SMuRFs (SMuRF‐less). SMuRF‐less patients had higher in‐hospital mortality (unadjusted hazard ratio [HR], 1.49 [95% CI, 1.19–1.87]). After adjustment for clinical characteristics and treatments, the associations between SMuRF status and in‐hospital mortality persisted (adjusted HR, 1.35 [95% CI, 1.07–1.70]). Guideline‐directed optimal medical therapy (receiving angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, β‐blockers, and statins) was not associated with lower mortality (adjusted HR, 0.98 [95% CI, 0.58–1.67]) in SMuRF‐less patients, unlike the association in patients with SMuRFs (adjusted HR, 0.80 [95% CI, 0.66–0.98]). Sensitivity analyses were consistent with these results. Conclusions: SMuRF‐less patients were associated with an increased risk of in‐hospital mortality. Guideline‐directed medical therapy was less effective in SMuRF‐less patients than in patients with SMuRFs. Dedicated studies are needed to confirm the optimal therapy for SMuRF‐less patients. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02306616.
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (19) , e029252
Open AccessIn‐Hospital Mortality and Treatment in Patients With Acute Coronary Syndrome With and Without Standard Modifiable Cardiovascular Risk Factors: Findings From the CCC‐ACS Project
Background: Patients with acute coronary syndrome without standard modifiable cardiovascular risk factors (SMuRFs; hypertension, smoking, dyslipidemia, diabetes) have not been well studied, with little known about their characteristics, quality of care, or outcomes. We sought to systematically analyze patients with ACS without SMuRFs, especially to evaluate the effectiveness of guideline‐directed medical therapy for these patients. Methods and Results: In the CCC‐ACS (Improving Care for Cardiovascular Disease in China‐Acute Coronary Syndrome) project (2014–2019), we examined the presence and absence of SMuRFs and features among 89 462 patients with initial acute coronary syndrome. The main outcome was in‐hospital all‐cause mortality. Among eligible patients, 11.0% had none of the SMuRFs (SMuRF‐less). SMuRF‐less patients had higher in‐hospital mortality (unadjusted hazard ratio [HR], 1.49 [95% CI, 1.19–1.87]). After adjustment for clinical characteristics and treatments, the associations between SMuRF status and in‐hospital mortality persisted (adjusted HR, 1.35 [95% CI, 1.07–1.70]). Guideline‐directed optimal medical therapy (receiving angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers, β‐blockers, and statins) was not associated with lower mortality (adjusted HR, 0.98 [95% CI, 0.58–1.67]) in SMuRF‐less patients, unlike the association in patients with SMuRFs (adjusted HR, 0.80 [95% CI, 0.66–0.98]). Sensitivity analyses were consistent with these results. Conclusions: SMuRF‐less patients were associated with an increased risk of in‐hospital mortality. Guideline‐directed medical therapy was less effective in SMuRF‐less patients than in patients with SMuRFs. Dedicated studies are needed to confirm the optimal therapy for SMuRF‐less patients. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02306616.
- Open Access
- 24 July 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (30) , e21312
Prediction of gastrointestinal bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention
Bleeding complications of acute coronary syndromes (ACS) after percutaneous coronary intervention (PCI) are strongly associated with adverse patient outcomes, and gastrointestinal bleeding (GIB) is the most common major bleeding event, especially in the early post-PCI period. Current guidelines recommend routinely conducting bleeding risk assessments. The existing tools are mainly used to evaluate the overall bleeding risk and guide the adjustment of antithrombotic strategies after 1 year. However, there are no specific tools for GIB risk assessment. Between January 2015 and June 2015, 4943 ACS patients underwent PCI were consecutively enrolled in the derivation cohort. GIB, cardiovascular, and cerebrovascular events were recorded within 1 year of follow-up. A validation cohort including 1000 patients who met the same inclusion and exclusion criteria was also established by propensity-score matching baseline characteristics. Multivariable cox proportional-hazards regression model was used to derive a risk-scoring system, and predictive variables were selected. A risk score nomogram based on the risk prediction model was created to estimate the 1-year risk of GIB. In this study, we found that the usage of clopidogrel (hazard ratio, HR: 2.52, 95% confidence intervals, CI: 1.573–4.021) and glycoprotein IIb/IIIa receptor inhibitors (HR: 1.863, 95% CI: 1.226–2.829), history of peptic ulcers (HR: 3.601, 95% CI: 1.226–2.829) or tumor (HR: 4.884, 95% CI: 1.226–2.829), and cardiac insufficiency (HR: 11.513, 95% CI: 7.282–18.202), renal insufficiency (HR: 2.010, 95% CI: 1.350–2.993), and prolonged activated partial thromboplastin time (HR: 4.639, 95% CI: 2.146–10.032) were independent risk factors for GIB 1 year after PCI. Based on these 7 factors, a nomogram and scoring system was established. The area under curve of risk score was 0.824 in the deviation cohort and 0.810 in the verification cohort. In both cohorts, the GIB score was significantly better than that of 3 classical bleeding scores (all P < .05). This score could well predict the risk of GIB within 1 year after PCI and could be used to guide antithrombotic strategies.
- 24 July 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (30) , e21312
Open AccessPrediction of gastrointestinal bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention
Bleeding complications of acute coronary syndromes (ACS) after percutaneous coronary intervention (PCI) are strongly associated with adverse patient outcomes, and gastrointestinal bleeding (GIB) is the most common major bleeding event, especially in the early post-PCI period. Current guidelines recommend routinely conducting bleeding risk assessments. The existing tools are mainly used to evaluate the overall bleeding risk and guide the adjustment of antithrombotic strategies after 1 year. However, there are no specific tools for GIB risk assessment. Between January 2015 and June 2015, 4943 ACS patients underwent PCI were consecutively enrolled in the derivation cohort. GIB, cardiovascular, and cerebrovascular events were recorded within 1 year of follow-up. A validation cohort including 1000 patients who met the same inclusion and exclusion criteria was also established by propensity-score matching baseline characteristics. Multivariable cox proportional-hazards regression model was used to derive a risk-scoring system, and predictive variables were selected. A risk score nomogram based on the risk prediction model was created to estimate the 1-year risk of GIB. In this study, we found that the usage of clopidogrel (hazard ratio, HR: 2.52, 95% confidence intervals, CI: 1.573–4.021) and glycoprotein IIb/IIIa receptor inhibitors (HR: 1.863, 95% CI: 1.226–2.829), history of peptic ulcers (HR: 3.601, 95% CI: 1.226–2.829) or tumor (HR: 4.884, 95% CI: 1.226–2.829), and cardiac insufficiency (HR: 11.513, 95% CI: 7.282–18.202), renal insufficiency (HR: 2.010, 95% CI: 1.350–2.993), and prolonged activated partial thromboplastin time (HR: 4.639, 95% CI: 2.146–10.032) were independent risk factors for GIB 1 year after PCI. Based on these 7 factors, a nomogram and scoring system was established. The area under curve of risk score was 0.824 in the deviation cohort and 0.810 in the verification cohort. In both cohorts, the GIB score was significantly better than that of 3 classical bleeding scores (all P < .05). This score could well predict the risk of GIB within 1 year after PCI and could be used to guide antithrombotic strategies.